Research programme: beta catenin inhibitors - Clinical Data

Drug Profile

Research programme: beta catenin inhibitors - Clinical Data

Alternative Names: 316; ATL 316; AV-65; AVB-08; AVB-63; AVB-92; AVN316; LC 363; LC-363 compounds

Latest Information Update: 27 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avalon Pharmaceuticals
  • Developer Clinical Data
  • Class Small molecules
  • Mechanism of Action Beta catenin inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 01 Apr 2012 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
  • 08 Dec 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top